Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data

Gregg, Edward W.; Cheng, Yiling J.; Srinivasan, Meera; Lin, Ji; Geiss, Linda S.; Albright, Ann; Imperatore, Giuseppina

doi:10.1016/s0140-6736(18)30314-3

Cited by 349 publications

(294 citation statements)

References 36 publications

Supporting

Mentioning

255

Contrasting

Order By: Relevance

“…Type 2 diabetes mellitus, the most frequently reported metabolic disorder in Western communities, has emerged as an important co‐morbidity producing functional impairment in older people. Although the effect of T2DM on risk of mortality in populations decreases with age, its effect on functional health becomes more noticeable as the population ages . The outcomes of intervention studies designed to improve functional status in older people at risk of disability (e.g.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus

Rodríguez‐Mañas

Laosa

Vellas

et al. 2019

J cachexia sarcopenia muscle

118

View full text Add to dashboard Cite

Background Type 2 diabetes, a highly prevalent chronic disease, is associated with increasing frailty and functional decline in older people. We aimed to evaluate the effectiveness of a multimodal intervention on functional performance in frail and pre‐frail participants aged ≥70 years with type 2 diabetes mellitus. Methods The MID‐Frail study was a cluster‐randomized multicenter clinical trial conducted in 74 trial sites across seven European countries. The trial recruited 964 participants who were aged >70 years [mean age in intervention group, 78.4 (SD 5.6) years, 49.2% male and 77.6 (SD 5.29) years, 52.4% male in usual care group], with type diabetes mellitus and determined to be frail or pre‐frail using Fried's frailty phenotype. Participants were allocated by trial site to follow either usual care (UCG) or intervention procedures (IG). Intervention group participants received a multimodal intervention composed of (i) an individualized and progressive resistance exercise programme for 16 weeks; (ii) a structured diabetes and nutritional educational programme over seven sessions; and (iii) Investigator‐linked training to ensure optimal diabetes care. Short Physical Performance Battery (SPPB) scores were used to assess change in functional performance at 12 months between the groups. An analysis of the cost‐effectiveness of the intervention was undertaken using the incremental cost‐effectiveness ratio (ICER). Secondary outcomes included mortality, hospitalization, institutionalization, quality of life, burden on caregivers, the frequency and severity of hypoglycaemia episodes, and the cost‐effectiveness of the intervention. Results After 12 months, IG participants had mean SPPB scores 0.85 points higher than those in the UCG (95% CI, 0.44 to 1.26, P < 0.0001). Dropouts were higher in frail participants and in the intervention group, but significant differences in SPPB between treatment groups remained consistent after sensitivity analysis. Estimates suggest a mean saving following intervention of 428.02 EUR (2016) per patient per year, with ICER analysis indicating a consistent benefit of the described health care intervention over usual care. No statistically significant differences between groups were detected in any of the other secondary outcomes. Conclusions We have demonstrated that a 12 month structured multimodal intervention programme across several clinical settings in different European countries leads to a clinically relevant and cost‐effective improvement in the functional status of older frail and pre‐frail participants with type 2 diabetes mellitus.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus

Rodríguez‐Mañas

Laosa

Vellas

et al. 2019

J cachexia sarcopenia muscle

118

View full text Add to dashboard Cite

show abstract

“…An observational study published in early 2018 analyzed the mortality burden associated with diabetes from among 35,000 randomly selected American households and the specific cause of death over time [11]. The prevalence of kidney disease in patients with diabetes remains high, although historically cardiovascular disease accounts for the majority of deaths.…”

Section: Diabetic Nephropathy: Hiddo Lambers Heerspink (The Netherlands)mentioning

confidence: 99%

Nephro Update Europe 2018

Kesel¹

2019

Kidney Dis

View full text Add to dashboard Cite

“…Diabetes mellitus (DM) is a serious public health concern and a huge economic burden in both developed and developing countries. DM is one of the leading causes of morbidity and mortality worldwide, affecting 340 million people in the world and leading to 4.6 million deaths each year . DM is a common chronic metabolic syndrome characterized by persistent high glucose levels, which can damage a variety of tissues and organs, resulting in severe complications in long term.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‐296‐5p promotes healing of diabetic wound by targeting sodium‐glucose transporter 2 (SGLT2)

Liu

Wang

Zhang

et al. 2018

Diabetes Metabolism Res

View full text Add to dashboard Cite

Background Diabetic wounds are refractory and very difficult to heal. We aimed to use miRNA to identify novel and specific molecular markers for diabetes mellitus (DM) diagnosis and treatment. Methods The expression level of miR‐296‐5p was determined in tissue samples of 12 DM patients. The effect of miR‐296‐5p on proliferation of β‐cells was examined using Cell Counting Kit‐8 (CCK‐8) and colony formation assay. The effect of miR‐296‐5p on cell cycle progression was analysed using flow cytometry. The target gene was verified using luciferase reporter assay. A rat diabetes model was used to assess the effect of miR‐296‐5p in vivo. Results Overexpression of miR‐296‐5p suppressed cell proliferation, arrested cell cycle progression, and increased the healing rate of diabetic wounds both in vivo and in vitro. TargetScan analysis results showed that miR‐296‐5p is a direct regulator of SGLT2. Conclusions miR‐296‐5p can increase the healing rate of diabetic wounds and may be an effective molecular tool in DM diagnosis and therapy.

show abstract

Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data

Abstract: None.

Cited by 349 publications

References 36 publications

Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus

Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus

Nephro Update Europe 2018

MicroRNA‐296‐5p promotes healing of diabetic wound by targeting sodium‐glucose transporter 2 (SGLT2)

Contact Info

Product

Resources

About